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Summary We have recently reported that about 30-40% of female breast tumours produce prostate-specific antigen (PSA) and that PSA
production is associated with the presence of oestrogen (ER) and progesterone (PR) receptors. We have now developed a tissue culture
system to study the regulation of the PSA gene in breast cancer. The breast carcinoma cell line T-47D produces PSA when stimulated by
androgens, progestins and glucocorticoids/mineralocorticoids but not oestrogens. PSA mRNA appears approximately 2 h after stimulation;
PSA protein appears after 4-8 h. Among 38 compounds tested, only androgens and progestins were able to stimulate PSA production at
concentrations below 10-9 M. Evidence that the progesterone and androgen receptors can regulate the PSA gene independently was provided
as follows: (a) the progestin norgestimate, which does not bind to the androgen receptor, up-regulates the PSA gene at concentrations as low
as 10-10 M; (b) triamicinolone acetonide, which does not bind to the androgen receptor (AR) but binds to the PR, acts similarly to norgestimate;
(c) the antiandrogen cyproterone acetate, which blocks the androgen receptor but has progestational activity, up-regulates the PSA gene at
concentrations as low as 10-10 M; (d) the antiprogestin mifepristone completely blocks the stimulation of the specific progestin norgestimate.
Our tissue culture system identified androgen - progestin agonist activities of 17a-ethinyloestradiol, the antioestrogen RU56, 187 and the
antiprogestin mifepristone. Our data suggest that the expression of the PSA gene in the female breast is under the control of androgens and
progestins. Our tissue culture system is a highly sensitive in vitro method for evaluating the biological activity of candidate compounds having
agonist and antagonist steroid hormone activity.
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Prostate-specific antigen (PSA) is a 33-kDa serine protease
produced at high concentrations by prostatic epithelial cells and
secreted into the seminal plasma. PSA production in the prostate is
regulated by androgens through the action of the androgen
receptor. Until recently, PSA was thought to be a prostatic tissue-
specific protein that is not expressed in any other tissue in men or
women. We have shown that PSA production occurs in the female
breast and some other tissues in both men and women (Diamandis
and Yu, 1995). Normal, benign and malignant breast tissue
produces PSA (Yu et al, 1995a); many malignant breast tumours
lose their ability to produce PSA. PSA appears to be a prognostic
indicator in breast cancer (Yu et al, 1995b). In our previous
studies, we have found that there is a close association between
PSA presence in breast tumours and presence of both oestrogen
and progesterone receptors; this association was stronger between
PSA and progesterone receptors (Yu et al, 1994a).
In order to investigate the mechanism ofPSA gene regulation in
the breast, we have developed a tissue culture system which repro-
duces in vitro the phenomenon of PSA production by breast cells.
The steroid hormone receptor-positive breast carcinoma cell line
T-47D does not produce detectable PSA when cultured in media
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devoid of steroid hormones (Yu et al, 1994b). When stimulated by
steroid hormones, this cell line produces PSA in a dose-dependent
manner. We have used this system to study the kinetics of PSA
production, the dose-response of PSA production by various
steroid hormones and the blocking effect of anti-hormones. We
provide evidence that the PSA gene in this cell line is regulated by
androgens and progestins.
METHODS
Compounds
All steroidal and non-steroidal compounds used in this study were
obtained from Sigma Chemical, St Louis, MO, USA, except for
the following: ICI 102, 780 and casodex (ICI 176, 334) (Zeneca
Pharma, Mississauga, ON, Canada); RU58, 668, RU54, 876,
RU56, 187, nilutamide (Anandron, RU23, 908) and mifepristone
(RU486, RU38, 486) (Roussel-UCLAF, Romainville, France).
Hydroxyflutamide was a gift from Dr Donna Peehl, Stanford
University. Stock solutions (10-2 or 10-3 M) were prepared in
absolute ethanol. More dilute solutions were also prepared in the
same solvent.
Stimulation experiments
The T-47D breast carcinoma cell line was obtained from the
American Type Culture Collection (ATCC), Rockville, MD, USA.
This cell line is positive for oestrogen, progesterone, androgen and
glucocorticoid receptors, although the amounts of each receptor
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are disputed (Glover and Darbre, 1989; Nordeen et al, 1989). T-
47D cells were cultured in RPMI media (Gibco BRL,
Gaithersburg, MD, USA) supplemented with glutamine (200
mmol 1-'), bovine insulin (10 mg 1-1), fetal bovine serum (10%),
antibiotics (penicillin, streptomycin) and antimycotics (ampho-
tericin B). The cells were cultured to near confluency in plastic
culture flasks and then transferred to phenol red-free media
containing 10% charcoal-stripped fetal bovine serum with antibi-
otics/antimycotics. Phenol red-free media were used as phenol red
was previously found to have weak oestrogenic activity (Berthois
et al, 1986) and charcoal-stripped fetal bovine serum is devoid of
steroid hormones.
The T-47D cells were then aliquoted into 24-well tissue culture
plates (Coming no. 25820) and cultured to confluency with change
in media at 3 days. Stimulations were carried out with confluent
cells containing 2 ml ofphenol red-free media with 10% charcoal-
stripped fetal calf serum and antibiotics/antimycotics. Stimulation
was initiated by adding 2 gl of each steroid dissolved in 100%
ethanol and incubating for a certain period oftime (usually up to 8
days). Tissue culture supermatants (-1-50 ,tl) were removed for
PSA analysis at days 3, 5 and 8. Slight modifications of this
protocol were introduced as necessary. Appropriate multiple posi-
tive and negative controls (only alcohol added) were included in
each experiment. Wells with microbial contamination were
excluded from the data analysis.
We also used the cell lines SAOS (osteosarcoma; provided by
Dr M Grynpas, Mount Sinai Hospital, Toronto, Canada) and BG-I
(ovarian carcinoma; provided by Dr H Rocheford, INSERM,
Montpellier, France) as well as the steroid hormone receptor-nega-
tive cell line BT-20 (breast carcinoma; obtained from ATCC).
These cell lines were treated similarly to the T-47D cells.
Dose-response experiments
For dose-response experiments, we followed the same protocol as
for stimulation, but steroids (2 gl per well) were added at various
concentrations. Steroid dilution in each well was 1000-fold in all
experiments as we added 2 pg of steroid solution in 2 ml of tissue
culture medium. The final concentration of each steroid was used
for data interpretation.
Blocking experiments
Blocking experiments were performed by simultaneously
checking for the following possibilities: (a) stimulation by the
blocker alone at a final concentration of 10-8 M; (b) stimulation by
the stimulating steroid alone at a final concentration of 10-9 M; (c)
adding the blocker to the cells at a final concentration of 10-8 M,
incubating for 1 h and then adding the stimulant at a concentration
of 10-9 M; (d) including controls with ethanol only (negative
controls). This protocol allows for a direct comparison ofthe stim-
ulating activity ofeither the blocker or the stimulant and the effect
ofthe blocker on the ability ofthe stimulant to induce PSA expres-
sion when the blocker is allowed to bind to the receptors at tenfold
higher concentrations for 1 h before the addition of the stimulant.
Kinetic experiments
The kinetics of PSA production by T-47D cells was studied as
follows: confluent T-47D cells were stimulated with norgestrel at a
final concentration of 10-8 M, and the cells were harvested along
with tissue culture supernatants at 1, 2, 4, 8, 24 and 48 h. Control
cells were harvested at 48 h without any stimulation (ethanol
added only). The tissue culture supernatants and a portion of the
cells were used for PSA protein analysis; another portion of the
cells was used to extract total RNA for polymerase chain reaction
(PCR) analysis of PSA mRNA.
Lysis procedure
The cell pellets were lysed for 30 min on ice with 1 ml of lysis
buffer. Lysis buffer was 50 mmol 1-' Tris, pH 8.0 containing 150
mmol 1-' sodium chloride, 5 mmol 1-' ethylenediaminetetraacetic
acid (EDTA), 10 g 1- nonidet NP-40 surfactant, 1 mmol 1-' phenyl-
methylsulphonyl fluoride and 1 mg 1-' each of aprotinin and
leupeptin as proteinase inhibitors. The lysate was centrifuged at
15 000 g at 4°C for 30 min, the supernatant was collected and
immediately assayed for PSA and total protein.
Measurement of PSA
PSA was measured with a highly sensitive immunofluorometric
procedure described in detail elsewhere (Ferguson et al, 1996).
This assay can measure PSA at levels of 10 ng 1-' or higher (up to
10 000 ng 1-') with a precision of<10%. All assays were performed
in duplicate. Tissue culture supermatants were measured undiluted
using 50 ,ul aliquots per assay. T-47D cells were detached by
trypsin-EDTA treatment, washed in phosphate-buffered saline and
then lysed in lysis buffer before analysis for PSA.
Measurement of total protein
Cell lysates were quantified for total protein using the bicin-
choninic acid (BCA) total protein method commercially available
by Pierce Chemical, Rockford, IL, USA.
Extraction of total RNA
Total RNA from T-47D cells was extracted using a commercial
reagent, TRIzol (Gibco BRL). The quality and quantity of the
extracted RNA was checked by spectrophotometric measurements
at 260 and 280 nm.
Reverse transcription
One microgram of total RNA was reverse transcribed using oligo
dT primers and Superscript II reverse transcriptase (Gibco BRL).
Briefly, RNA and oligo (dT) primers (500 ng) were first denatured
for 10 min at 70°C, chilled on ice for 1 min and then incubated for
I h at 42°C in a 20-,ul reaction mixture containing 1 x PCR buffer,
2.5 mm magnesium chloride, 1 mm deoxynucleoside triphos-
phates, 10 mM dithiothreitol and 200 units ofSuperscript II reverse
transcriptase. The reaction was terminated by heating for 15 min at
70°C. Template RNA was digested by incubation with RNAase H
for 20 min at 37°C.
Oligonucleotide primers
We have used two oligonucleotides to amplify the cDNA of PSA
with the polymerase chain reaction (PCR). These were originally
proposed by Deguchi et al (1993) and they have the following
sequences:
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Figure 1 RT-PCR of PSA mRNA extracted from T-47D cells. (A) Ethidium
bromide-stained agarose gel; (B) The gel was Southern-transferred and the
PCR product, in which digoxigenin-dUTP was incorporated during PCR, was
detected with anti-digoxigenin antibodies and chemiluminescence. Lanes 1
and 7: T-47D cells were stimulated with absolute alcohol (solvent) and mRNA
extracted at the beginning (0 time) or at the end (48 h) of the experiment
respectively. Lanes 2, 3,4,5,6 and 8. The T-47D cells were stimulated with
10-8 M norgestrel once and mRNA extracted after 1 h (lane 2), 2 h (lane 3),
4 h (lane 4), 8 h (lane 5), 24 h (lane 6) and 48 h (lane 8). MW markers,
molecular weight markers. The PCR product is 754 bp in size. Actin RT-PCR
was performed in all cDNAs from lanes 1-8 and it was positive in all cases
(data not shown)
PSA-1: 5'-TGC-GCA-AGT-TCA-CCC-TCA-3'
PSA-2: 5'-CCC-TCT-CCT-TAC-TTC-ATC-C-3'
These primers amplify a 754-bp fragment of PSA cDNA. Actin
primers were used as controls; their sequences have been
described previously (Okazaki, 1992). Actin primers amplify a
372-bp fragment of actin cDNA.
PCR procedure
One microlitre of cDNA was added to 49 ,l of PCR mix
containing 1 x PCR buffer (Boehringer Mannheim), 2.5 mM
magnesium chloride, 500 nm ofPCR primers, 200 gM ofdeoxynu-
cleoside triphosphates and 1.25 units of Taq DNA polymerase
(Boehringer Mannheinm). PCR was performed for 30 cycles
according to the following programme on the Perkin-Elmer 2400
thermal cycler: 94°C for 30 s (5 min for the first cycle), 60°C for
30 s: and 72°C for 30 s (7 min for the last extension). Actin cDNA
was amplified from 1 gl of the cDNA preparation under the same
conditions used for PSA cDNA. Fifteen microlitres of each PCR
reaction were electrophoresed on 2% agarose gels and visualized
by ethidium bromide staining. In other experiments, during the
PCR reaction, we incorporated digoxigenin- 11-dUTP and detected
the PCR product after Southern transfer to nylon membranes and
c,)
a-
CL
100
Time (h)
Figure 2 Appearance of PSA mRNA and PSA protein intracellularly (E) or
in the tissue culture supernatant (*) following stimulation of T-47D cells with
10-8 M norgestrel. The post-stimulation time of first appearance of PSA
mRNA is 2 h, of intracellular PSA protein is 4 h and of PSA protein in tissue
culture supernatant is 8 h. Cells not stimulated at all (data not shown) or
stimulated with ethanol did not produce PSA mRNA or protein during the 48
h duration of this experiment. No PSA mRNA or protein was seen in
norgestrel-stimulated or unstimulated BT-20 breast carcinoma cell lines (data
not shown)
probing with anti-digoxigenin antibodies conjugated to alkaline
phosphatase (ALP). ALP activity was detected with chemilumi-
nescence. This method is about 50 times more sensitive than
ethidium bromide staining in detecting the PCR products.
Digoxigenin-1 l-dUTP (Boehringer) was added in the PCR mix at
a concentration of0.7 gm.
Sequencing of PCR products
Total RNA was extracted from norgestrel-stimulated T-47D cells,
reverse transcribed and amplified as described above. The PCR
product was sequenced with the Thermo Sequenase fluorescent
labelled primer cycle sequencing kit (Amersham International,
Buckinghamshire, UK) following the recommendations of the
manufacturer. Our sequencing primers, labelled at the 5'-end with
CY.5 fluorescent dye, had the following sequences: PSA-S1: 5'-
AAGGTGACCAAGTTCATG-3' (binds 19 bases internally from
PCR primer PSA-1). PSA-S2: 5'-CCATCCCATGCCAAAGGA-3'
(binds 19 bases internally from PCR primer PSA-2). All
sequencing reactions were loaded on the ALF Express automatic
sequencer (Pharmacia Biotech, Uppsala, Sweden).
RESULTS
The breast carcinoma cell line T-47D was cultured in the absence of
any stimulating steroid and in the presence of the stimulating
steroid norgestrel at a concentration of 10-8 M. The appearance of
PSA mRNA was monitored with reverse transcription-polymerase
chain reaction (RT-PCR). The appearance ofPSA protein inside and
outside ofthe cell (secreted protein) was monitored by the immuno-
assay procedure. The results are summarized in Figures 1 and 2.
PSA mRNA is undetectable in either unstimulated cells, cells
stimulated with ethanol for up to 48 h or cells stimulated with
norgestrel after 1 h post-stimulation. PSA mRNA becomes detect-
able in the norgestrel-stimulated cells at 2 h, its concentration
increases at 4 h and it persists for at least 48 h (Figure 1). However,
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Figure 3 Representative chromatogram of an 82-nucleotide region of the PSA cDNA sequence from norgestrel-stimulated T-47D cells. For details see text
1 GCTCGGGTGA
51 ATCACGTCAT
101 GTACACCAAG
151 CCAACCCCTG
201 TTGGAAATGA
251 GTCCTTAGGT
301 AGGTGTAGAC
351 TCCTGGGGAA
401 GGACACAGAT
451 AAGAGGGGTG
501 ACTGTCCATG
551 TCACAGCAAG
TTCTGGGGGC CCACTTGTCT
GGGGCAGTGA ACCATGTGCC
GTGGTGCATT ACCGGAAGTG
AGCACCCCTA TCAACTCCCT
CCAGGCCAAG ACTCAGGCCT
GTGAGGTCCA GGGTTGCTAG
CAGAGTGTTT CTTAAATGGT
TACTGGCCAT GCCTGGAGAC
AGGATGGGGT GTCTGTGTTA
GGATCCACAC TGAGAGAGTG
AAGCACTGAG CAGAAGCTGG
GATGGAGCTG AAAACATAAC
GTAATGGTGT GCTTCAAGGT
CTGCCCGAAA GGCCTTCCCT
GATCAAGGAC ACCATCGTGG
ATTGTAGTAA ACTTGGAACC
CCCCAGTTCT ACTGACCTTT
GAAAAGAAAT CAGCAGACAC
GTAATTTTGT CCTCTCTGTG
ATATCACTCA ATTTCTCTGA
TTTGTGGGGT ACAGAGATGA
GAGAGTGACA TGTGCTGGAC
AGGCACAACG CACCAGACAC
CCACTCTGTC CTGGAGGCAC
601 TGGGAAGCCT AGAGAA
Figure 4 Complete sequence of the 616 nucleotide region of the PSA cDNA sequence from norgestrel-stimulated T-47D cells. For discussion, see text. Bold
and underline indicate end of exon 4 and exon 5 respectively
this test is semiquantitative. Quantitative information was provided
by protein data. PSA protein is first detected in the cell cytoplasm
4 h after stimulation by Norgestrel and accumulates over the 48-h
study period. PSA secreted into the culture medium is first detected
at 8 h, and its concentration increases rapidly with time (Figure 2).
An identical experiment was performed using the steroid
hormone receptor-negative breast carcinoma cell line BT-20. This
cell line did not produce any detectable PSA mRNA or protein
after stimulation with norgestrel at the indicated time periods (data
not shown).
The identity of the PCR product was verified by complete
sequencing of both strands. Partial sequencing data are shown in
Figure 3. The entire sequence is shown in Figure 4. The sequence,
spanning 616 nucleotides from exons 4, 5 and the 3'-untranslated
region, is >99% homologous to the published sequence of PSA
cDNA or genomic DNA. We found 100% homology with the
sequence published by Lundwall (1989), Digby et al (1989) and
Klobeck et al (1989).
There is one base difference (A to G) at position 439 (3'-
untranslated region) of our sequence and the sequence published
by Lundwall and Lilja (1987), Shultz et al (1988), Henttu and
Vihko (1989) and Riegman et al (1988). Also, at position 419 (3'-
untranslated region), we and others have identified G but a few
other investigators have identified T. These differences are likely
polymorphisms.
Comparison of our 616 nucleotide sequence with the sequence
of human glandular kallikrein gene revealed only about 80%
homology. These data confirm that the mRNA isolated from
norgestrel-stimulated T-47D cells is indeed the PSA mRNA.
In order to establish which of the compounds shown in Table 1
act as PSA gene regulators, we stimulated T-47D cells and
measured PSA in the tissue culture supernatant at 3, 5 and 8 days
after single stimulation at a compound concentration of 10-7M. The
compounds were then qualitatively categorized into three groups:
non-stimulators, weak stimulators and strong stimulators. For this
classification, we arbitrarily selected a supernatant PSA concen-
tration at 8 days of >200 ng 1-1, 10-200 ng 1-' or <10 ng 1-' for
strong, weak and non-stimulators respectively. Some stimulation
data are shown graphically in Figure 5; detailed data are summa-
rized in Table 1.
Dose-response experiments were designed to determine the
lowest concentration of stimulating steroids which could still
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Table 1 Regulation of PSA gene expression by various compounds
Compound Major biological activity PSA production at 10-7M Lowest concentration for response (M)
Testosterone Androgen Stronga 10-10
Dihydroandrosterone Androgen Strong < 10 11
Androsterone Androgen Strong 10-10
R1881 (Methyltrienolone) Androgen Strong ND
R5020 Androgen/progestin Strong ND
Dihydrotestosterone Androgen Strong < 10
Dihydroisoandrosterone sulphate (DHEA-SO4) Androgen metabolite Nothinga
Oestrone Oestrogen Nothing
Oestriol Oestrogen metabolite Nothing
17 a-Ethynyloestradiol Oestrogen Weaka 104
f-Oestradiol Oestrogen Nothing
Corticosterone Glucocorticoid Weak 10-7
Hydrocortisone Glucocorticoid Nothing
Betamethasone 17-valerate Glucocorticoid Strong ND
Dexamethasone Glucocorticoid Strong 10-8
Prednisone Glucocorticoid Nothing
1 7a-Hydroxyprogesterone Progesterone precursor Nothing
Progesterone Progestin Weak 10-10
Norethynodrel Progestin Strong ND
Norethidrone Progestin Strong ND
Norgestrel Progestin Strong < 10 11
Depo-provera Progestin Strong < 10 11
Norgestimate Progestin Strong 10-10
Aldosterone Mineralocorticoid Weak 104
Triamicinolone acetonide Progestin/glucocorticoid Strong 10-10
Tamoxifen Antioestrogen Nothing
ICI 182, 780 Antioestrogen Nothing
RU 58, 668 Antioestrogen Nothing
RU 54, 876 Antioestrogen Nothing
Hydroxyflutamide Antiandrogen Nothing
Cyproterone acetate Antiandrogen/progestin Strong 10-10
Casodex (ICI 176, 334) Antiandrogen Nothing
RU56, 187 Antiandrogen Weak 104
Nilutamide (Anandron) Antiandrogen Nothing
Mifepristone (RU486/RU38, 486) Antiprogestin Weak 104
Cortexolone Antiglucocorticoid Weak 10-7
Spironolactone Antimineralocorticoid Weak 10-7
Cholesterol Steroid hormone precursor Nothing
Alcohol Nothing (solvent) Nothing
aFor definition, see text. ND, not done.
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Figure 5 PSA concentration in T-47D cell line tissue culture supernatants after a single 10-7 M stimulation with various compounds and sampling of the
supernatants at 3 (-), 5 (0) and 8 (A) days after stimulation. The compounds tested were: 1, testosterone; 2, oestrone; 3, vitamin D; 4, corticosterone; 5,
dihydroandrosterone; 6, oestriol; 7, 17a-hydroxyprogesterone; 8, androsterone; 9, hydrocortisone; 10, 17a-ethynyloestradiol; 11, norethynodrel; 12, tamoxifen;
13, ,-oestradiol; 14, betamethasone-17-valerate; 15, norethidrone; 16, norgestrel; 17, aldosterone; 18, dexamethasone; 19, cholesterol; 20, R1881; 21, R5020;
22, 23, no stimulation; 24, alcohol. In all cases the most dramatic change in PSA concentration occurs in the interval between 3 and 6 days. The strongest
stimulators are androgens (1, 5, 8, 20, 21) and progestins (11, 15, 16). More data are given in Table 1
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Figure 6 Dose-response experiments of six representative steroids. For more details and discussion, see text
induce production of PSA. Representative dose-response experi-
ments are shown in Figure 6. The lowest concentration of stimu-
lating steroids which could induce PSA production is shown in
Table 1. Among the steroids tested, the most potent were two
androgens (dihydroandrosterone and dihydrotestosterone) and two
synthetic progestins (norgestrel and Depo-provera). These four
steroids could induce PSA production at final concentrations down
to 10-" M. Two other androgens (testosterone and androsterone)
and a synthetic progestin (Norgestimate) were potent at concentra-
tions down to 10-10 M. 17x-Ethinyloestradiol, unlike the other
oestrogens tested, was able to regulate PSA production positively,
but only at relatively high concentrations (10-7-10-8 M). Among
the glucocorticoids, corticosterone was a weak stimulator whereas
betamethazone and dexamethazone were strong stimulators, but
only at concentrations .10-8 M. Aldosterone was a weak stimulator
but the synthetic compound triamicinolone acetonide (TA) was a
strong stimulator, acting at low concentrations (10-10 M). None of
the antioestrogens exhibited stimulatory activity. Among the
antiandrogens, some did not induce any PSA production, one was
a weak stimulator (RU 56, 187) and one (cyproterone acetate) was
a strong stimulator, acting at concentrations as low as 10-
0 M. The
antiprogestin mifepristone (RU 38, 486; RU 486) as well as the
antiglucocorticoid cortexolone and the antimineralocorticoid
spironolactone were weak stimulators, acting at concentrations
10-7-l0-8 M. The androgen metabolite dihydroisoandrosterone
sulphate and the progesterone precursor 170x-hydroxyprogesterone
were inactive. Dose-response experiments with the oestrogens
oestrone and oestradiol have shown that these compounds remain
inactive with respect to PSA gene up-regulation at any concentra-
tion between 10-7 and 10-10 M.
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Table 2 Blocking of PSA production in T-47D cells by various compoundsa
Blocking compound Blocking of Blocking of Blocking of
Stimulating compound (10-9M (10-8M Dihyrotestosteroneb (%) Norgestreib (%) Norgestimateb (%)
Dihydrotestosterone Oestradiol 50-80 9-12 0
or Nilutamide 20-40 0-15 0
Norgestrel RU 56,187 85-91 17-40 0
or Hydroxyflutamide 30-33 0-20 0
Norgestimate ICI 182, 780 0 10-20 0
Mifepristone 70-80 90-100 100
Spironolactone 0 0 0
Cortexolone 0 0 0
aFor detailed protocol refer to Methods section. bRange of three different experiments.
Stimulation experiments were further conducted using the
steroid hormone receptor-genomic negative breast carcinoma cell
line BT-20 and the steroid hormone receptor-positive cell lines
SAOS (osteosarcoma) and BG-1 (ovarian carcinoma). None ofthe
compounds listed in Table 1 was able to induce detectable PSA
protein production.
In order to further elucidate the mechanism ofregulation ofPSA
production by steroid hormones, we have conducted blocking
experiments. In these studies, we have first treated the T-47D cells
with a steroid hormone receptor blocker for 1 h followed by the
addition of a tenfold lower concentration of a stimulating steroid.
The data are presented in Table 2.
Oestradiol, as well as the antiandrogens nilutamide, RU56, 187
and hydroxyflutamide, was able to block significantly the stimu-
lating action of dihydrotestosterone. Mifepristone was also a
potent blocker; no blocking activity was seen among the antioe-
strogen ICI 182, 780 the antimineralocorticoid spironolactone and
the antiglucocorticoid cortexolone.
The stimulatory activity ofnorgestrel was blocked minimally by
oestradiol, nilutamide, hydroxyflutamide and ICI 182, 780 and to
a higher degree by RU 56, 187. The most potent blocker of
norgestrel's action was the antiprogestin mifepristone (blocking
90-100%).
The stimulatory activity ofthe highly selective progestin agonist
norgestimate was only blocked by the antiprogestin mifepristone
(blocking 100%).
DISCUSSION
The PSA gene is known to be regulated by androgens in the male
prostate (Henttu et al, 1992; Levine, 1995). The epithelial cells of
the prostate gland are rich in AR; some stromal cells also contain
AR, as well as the enzyme 50x-reductase, which reduces testosterone
to dihydrotestosterone (Levine, 1995). The PSA gene has a hormone
response element (HRE) to which the activated AR can bind
(Klobeck et al, 1989; Riegman et al, 1991; Murtha et al, 1993; Luke
and Coffey, 1994). The PSA gene is up-regulated by androgens and
androgen agonists and is down-regulated by antiandrogens.
We have recently shown that female breast tissue and breast
secretions contain high levels of PSA (Diamandis and Yu, 1995).
Although the physiological role ofthis protein in the female breast
is still unknown, we have demonstrated that the presence ofPSA is
strongly associated with presence of steroid hormone receptors
(Yu et al, 1994a). We have thus postulated that the PSA gene in the
female breast is regulated by steroid hormones. In this study, we
have developed a tissue culture system to further examine this
regulation and study the involvement of the various steroid
hormone receptors.
We have first shown that the steroid hormone receptor-positive
breast carcinoma cell line T-47D is capable of producing PSA
under appropriate stimulation by steroid hormones. T-47D cells, as
well as MCF-7 cells, do not produce PSA in the absence ofsteroid
hormones (Yu et al, 1994b; Smith et al, 1995). The PSA mRNA
produced by T-47D cells is, identical to the sequence of PSA
mRNA from prostate cells. In contrast, the breast carcinoma cell
line BT-20, which is devoid of steroid hormone receptors, did not
produce PSA after stimulation by any of the compounds listed in
Table 1. We have thus postulated that PSA production by breast
cells is dependent on the steroid hormone-steroid hormone
receptor system. We further demonstrated that the receptors and
hormones are necessary but not sufficient for PSA production.
When we stimulated the steroid hormone receptor-positive cell
lines SAOS (osteosarcoma) and BG-1 (ovarian carcinoma) with
the compounds shown in Table 1, none was able to induce PSA
production. The presence of oestrogen and progesterone receptors
in these cell lines was confirmed by analysis with established
enzyme immunoassay kits (data not shown). Apparently, either
post-receptor defects are present in these cell lines, the receptors
are defective or the promoter of the PSA gene in these cell lines is
tissue specific. These possibilities were not studied further.
Among all androgenic compounds tested, only dihydroiso-
androsterone sulphate, an inactive metabolite, was not able to stim-
ulate PSA production. All other androgens were strong stimulators
(Table 1). The physiological androgens testosterone and andros-
terone and their reduced forms dihydrotestosterone and dihydroan-
drosterone were able to induce PSA production at levels as low as
10-1u M and 10-11 M respectively. The lower active concentration of
dihydrotestosterone (and dihydroandrosterone) is in accord with its
higher affinity for the androgen receptor than testosterone (Levine,
1995). Strong stimulation was also observed with the synthetic
compounds R1881 and R5020. In all cases tested, we observed a
dose-response relationship. Although there is always a degree of
cross-reactivity of steroid hormones with receptors other than the
cognate receptors, the activity ofandrogens at levels around 10' M
(a concentration 10- to 100-fold lower than the affinity constant of
the testosterone - AR complex) strongly suggests that the effect is
mediated through high-affinity binding to the androgen receptor
and not through low-affinity binding to cross-reacting receptors.
Among the four oestrogens tested, the three natural oestrogens -
oestradiol, oestrone and oestriol -did not mediate any PSA produc-
tion. These data suggest that the oestrogen receptor is not involved
in PSA gene up-regulation in the breast carcinoma cell line T-47D.
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17ax-Ethinyloestradiol, a synthetic oestrogen, was a weak but
consistent stimulator at concentrations .10-8 M, suggesting that this
steroid is not a pure oestrogen. Our data suggest that this steroid
interacts with the androgen and/or the progesterone receptor
leading to active complexes capable of weakly upregulating the
PSA gene.
Among the group of glucocorticoids tested, the physiological
glucocorticoid hydrocortisone and the synthetic glucocorticoid
prednisone had no effect. The strong induction of betamethasone
and dexamethasone and the weak induction by corticosterone (at
concentrations 2 10-8 M), all ofwhich have higher affinities for the
glucocorticoid receptor than hydrocortisone and cortisone and do
not bind to either AR or PR (Ojasoo et al, 1988), suggest that the
glucocorticoid receptor is capable of regulating the PSA gene as
well. The PSA stimulation, at high glucocorticoid concentrations
only, may reflect the low concentration of this receptor in T-47D
cells (Glover and Darbre, 1989; Nordeen et al, 1989).
With the exception of the inactive progesterone precursor 17ax-
hydroxyprogesterone, all other progesterone agonists tested were
strong stimulators of PSA production. In dose-response experi-
ments, we have shown that the three tested progestins were active
at levels 10-10-10 M. In particular, norgestimate, which exhibits
highly specific high-affinity binding to the progesterone receptor
than other progestin agonists (Phillips, 1990; Kafrissen, 1992;
Phillips et al, 1992) and binds to androgen receptor very poorly,
was active at levels down to 10-10 M. The data presented for the
progestin agonists, in combination with data from blocking exper-
iments (discussed below), strongly suggest that the progesterone
receptor, activated by progestin, is capable of directly up-regu-
lating the PSA gene.
In men, PSA gene regulation is under the control of testicular
androgens through the androgen receptor. We speculate that in
women, PSA gene regulation in organs such as the breast and the
endrometrium (Clements and Mukhtar, 1994) is mediatedby prog-
estins and androgens through the independent action ofthe proges-
terone and the androgen receptor.
Aldosterone, a natural mineralocorticoid, was capable of PSA
regulation only weakly and at concentrations >10-8 M.
Triamicinolone acetonide, a compound known to interact with
the PR and GR but not the androgen receptor (Zava et al, 1979;
Ojasoo et al, 1988) was found to strongly stimulate PSA produc-
tion at concentrations as low as 10-10 M. This finding further
strengthens our suggestion that the progesterone and glucocorti-
coid receptor can mediate PSA production without involvement of
the AR.
Among the four antioestrogens, none was able to mediate PSA
production consistent with the suggestion that the oestrogen
receptor is not involved in PSA gene up-regulation. Among the
group ofantiandrogens, we observed some interesting phenomena.
All these compounds bind to the androgen receptor leading to
either inactive complexes (pure antiandrogens) or to complexes
with somebiological stimulatory activity (antiandrogens with weak
agonist activity). In our system, hydroxyflutamide, casodex and
nilutamide (anandron), which are known to bind to the androgen
receptor with low affinity (<2% oftestosterone affinity) (Teutsch et
al, 1994), did not mediate any PSA production, suggesting forma-
tion of weak and inactive complexes with the androgen receptor.
Cyproterone acetate, which binds to the androgen receptor with
affinity approximately 10% of that of testosterone (Teutsch et al,
1994), was found to be a strong stimulator ofPSA production, with
activity even at concentrations of approximately 10-10 M. These
data suggest that cyproterone acetate, a known antiandrogen that
also interacts with the progesterone receptor (Teutsch et al., 1994;
Levine, 1995) and has biological progestational activity (Levine,
1995), exerts its action on PSA regulation through binding to the
progesterone receptor. Our finding that cyproterone acetate can up-
regulate the PSA gene through the progesterone receptor in parallel
to its expected down regulation of the PSA gene through androgen
receptor blockade requires further investigation as monitoring PSA
levels during cyproterone acetate treatment of prostate cancer may
not be a reliable index of clinical response. Up-regulation of the
PSA gene by cyproterone acetate through its progestational activity
has not, to our knowledge, as yet been reported. It is currently
unknown if this indeed happens in prostate cells in addition to
breast cancer cell lines.
The newer antiandrogen RU56, 187 has affinity for the
androgen receptor similar to testosterone but no detectable affinity
for progesterone, glucocorticoid, mineralocorticoid or oestrogen
receptors (Teutsch et al, 1994). In our system, we detected weak
PSA gene up-regulation at RU56, 187 concentration .10-8 M. This
up-regulation strongly suggests that RU56,187 has weak androgen
agonist activity. In this respect, our tissue culture system appears
to be more sensitive than the in vitro systems used by Teutsch et al
(1994) to evaluate RU56,187, concluding that this compound is
totally devoid of binding to other steroid receptors and of any
agonist effect. It remains to be determined if the weak agonist
activity ofRU56,187 has any biological significance.
Mifepristone (RU486, RU38,486) is a new antiprogestational
agent with antiglucocorticoid and antiandrogenic activity. RU486
has been commercialized as an antiprogestin for first trimester
pregnancy interruption. In our system, we found that Mifepristone
has weak agonist activity, mediating PSA gene up-regulation at
concentrations .10-8 M. This agonist activity was not observed by
Philibert et al (1985), further suggesting that their biological tests
are not as sensitive as our tissue culture system in detecting such
an effect. In support of our data are reports by others showing
weak agonist activity of RU486 in various systems (Gravanis et
al, 1985; Gronemeyer et al, 1991; Wehle et al, 1995). It remains
to be seen if the weak agonist activity of mifepristone is
mediated by the androgen, glucocorticoid or the progesterone
receptor. Very weak agonist activity was also observed for the
antiglucocorticoid cortexolone and the antimineralocorticoid
spironolactone at concentrations 2 10-7 M.
While oestradiol has no positive effect on PSA gene regulation,
blocking experiments have revealed that oestradiol could block the
action of dihydrotestosterone and to a much lesser degree
norgestrel but not norgestimate on PSA gene regulation (Table 2).
There are two possible explanations for this phenomenon. First,
high doses of oestradiol could cause its binding to the androgen
receptor thus blocking the action ofdihydrotestosterone (Ojasoo et
al, 1988; Lea et al, 1989). Second, oestradiol would bind to the
oestrogen receptor in T-47D cells and the active complex would
further inhibit the action of active AR complexes. Active ER, AR
and PR complexes compete for the same transcription factors
including c-jun and c-fos as suggested previously (Pearce and
Yamamoto, 1993). The fact that oestradiol blocks the stimulation
by dihydrotestosterone but not the stimulation by norgestimate
suggests that oestradiol blockade targets the AR but not the PR.
Our finding of positive regulation of the PSA gene by androgen
and progestin and the negative regulation by oestrogen suggests
that PSA is regulated by a delicate balance between androgens,
progestins and oestrogens.
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Nilutamide and hydroxyflutamide, two antiandrogens that bind
with low affinity to the androgen receptor, had moderate but not
complete blocking activity (-30-40% on average) on dihy-
drotestosterone and an even lower blocking activity (<20%) on
norgestrel and no blocking activity on norgestimate. These data are
expected as the stimulating steroids (e.g. dihydrotestosterone),
having higher affinity for the androgen receptor, would displace a
fraction of the blocker after they are added into the tissue culture
system. On the other hand, RU56, 187, which has an affinity for
the androgen receptor similar to testosterone, was able to block
85-91% ofthe activity ofdihydrotestosterone. The lower blockade
on norgestrel action (17-40% on average) and the absence of
blockade on norgestimate action further suggests that a significant
portion of norgestrel's and 100% of norgestimate's stimulation is
mediated through the progesterone receptor to which RU56, 187
does not bind and could not block.
The antioestrogen ICI 182, 780 had little or no blocking effect
on the stimulation of PSA production by dihydrotestosterone,
norgestrel or norgestimate, in accordance with our view that the
oestrogen receptor does not positively mediate PSA production in
our system.
Mifepristone was an effective blocker of PSA production by
dihydrotestosterone (70-80%) and an almost complete blocker of
norgestrel and norgestimate (90-100%). This is in accord with our
view that PSA production is mediated independently by the AR
and the PR as mifepristone is known to block effectively the prog-
esterone receptor and to a lesser but significant degree the
androgen receptor (Philibert et al, 1985).
As expected, the antiglucocorticoid cortexolone and the anti-
mineralocorticoid spironolactone had no effect on either dihy-
drotestosterone, norgestrel or norgestimate action as these two
anti-hormones bind primarily to GR and MR and only with low
affinity to other receptors that are involved in PSA production.
Taken together, our data suggest the following: the breast carci-
noma cell line T-47D has the necessary receptors and other tran-
scriptional machinery to produce PSA. Once stimulated by a
steroid hormone, T-47D cells produce PSA mRNA within 1-2 h,
synthesize detectable intracellular protein within 4 h and secrete
detectable protein within 8 h. PSA gene regulation is under the
control of androgens and progestins through the independent
action ofthe androgen and progesterone receptors (positive regula-
tion). Weak positive regulation may also be effected by high
concentrations of glucocorticoids and mineralocorticoids. Oestro-
gens do not positively regulate the PSA gene but they act as
blockers of androgen action. The most effective blockers of PSA
gene regulation were found to be the anti-androgen RU56, 187 and
the antiprogestin mifepristone. Our data, showing multihormone
regulation of the PSA gene, are in accord with these of Glover and
Darbe (1989) who concluded the same using T-47D cells trans-
fected with the mammary tumour virus long terminal repeat
sequences.
Our tissue culture system not only reproduces the phenomenon
of PSA production by breast cancers but it also offers a means of
testing the biological activity of candidate new hormonal and
anti-hormonal agents. With this system, we have shown that
two new anti-hormones, the antiandrogen RU56, 187 and the
antiprogestin mifepristone, which were found to be completely
devoid of agonist activity by traditional in vivo and in vitro tech-
niques, have low but detectable androgen and/or progestin
agonist activity demonstrated by their ability to upregulate the
PSA gene.
Recently, we have obtained evidence that the progestin-medi-
ated upregulation of the PSA gene occurs in vivo as well. We have
reported PSA production by normal breast tissue in a female
patient who was receiving an oral contraceptive containing
norethidrone (Yu et al, 1995). PSA regulation by progestins in the
prostate has not been reported but it is known that the prostate
cells, in addition to AR, also contain PR (Mobbs and Liu, 1990). In
another report, we described a patient who was receiving high
doses of glucocorticoids and had an ovarian tumour producing
PSA (Yu et al, 1995c).
Our data further supports the view that PSA may be regulated in
diverse tissues containing PR. Tissues which contain PR include
the breast (Yu et al, 1994a), the endometrium (Clements and
Mukhtar, 1994), brain meningiomas (Carrol et al, 1993), blood
vessel walls (Bergqvist et al, 1993), urinary tract (Pacchioni et al,
1992) and osteoclasts (Boivin et al, 1994). In view of these and
other findings, we believe that it is time to study in detail the
biological role of PSA in non-prostatic tissues. The presence of a
significant prognostic value of this molecule in breast cancer (Yu
et al, 1995b) suggests that this elegantly regulated enzyme may
play some role in breast cancer initiation and progression.
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